Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

March 25th 2025

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

In SCLC, transcription factors have also been found to play a key role in chemoresistance, and differences in expression of transcription factors have been tied to drug sensitivities. | Image credit: Rasi-stock.adobe.com
Examination of FOXP1 in SCLC Yields Potential Strategy Against Chemoresistance

March 20th 2025

Lung cancer illustration | Image credit: SciePro - stock.adobe.com
Use of AI Lets Health System Find Lung Cancer at Early Stages

March 8th 2025

lung cancer | Image credit: Crystal light - stock.adobe.com
Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

March 5th 2025

radiology x-ray lung cancer | Image credit: utah51 – stock.adobe.com
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer

February 17th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

More News

Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
September 23rd 2022

Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Picture of cancer researchers
September 21st 2022

Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC

Jaime Rosenberg
With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Ticiana Leal, MD, Emory University School of Medicine
September 14th 2022

Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal

Laura Joszt, MA Skylar Jeremias
Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
lung cancer
September 12th 2022

Lung Cancer Screening Leads to Earlier Diagnosis, but Not Overdiagnosis

Jared Kaltwasser
A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
September 10th 2022

Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs

Maggie L. Shaw Hayden E. Klein
Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.
picture of patient consulting provider
September 8th 2022

Recommendations to Safeguard Quality Shared Decision-Making for Lung Cancer Screening

Allison Inserro
An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
August 29th 2022

Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC

Hayden E. Klein Maggie L. Shaw
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Colorful lung graphic
August 23rd 2022

Clinicians Slow to Adopt PD-1, PD-L1 Inhibitors in NSCLC

Jared Kaltwasser
A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.
Evaluating and Integrating New Data Into NSCLC Clinical Pathways
August 18th 2022

Evaluating and Integrating New Data Into NSCLC Clinical Pathways

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.
Immune Checkpoint Inhibitors in NSCLC Therapy
August 18th 2022

Immune Checkpoint Inhibitors in NSCLC Therapy

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.
Ticiana Leal, MD
August 17th 2022

HER2m NSCLC an “Exciting Area of Active Investigation,” Says Dr Ticiana Leal

Laura Joszt, MA
Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Trilaciclib Before Chemotherapy May Prevent Hematological Events—With Savings
August 16th 2022

Trilaciclib Before Chemotherapy May Prevent Hematological Events—With Savings

Mary Caffrey
Caregivers
August 15th 2022

Caregivers of Patients With Early-Stage Lung Cancer Face Anxiety, Moderate Burden

Jared Kaltwasser
Health care providers can help alleviate caregiver burdens by teaching coping strategies, the authors said.
Image of a telemedicine appointment
August 12th 2022

Targeted Outreach Efforts Meaningful for Patients With Lung Cancer

Jared Kaltwasser
Patients were more likely to accept intervention from a psychologist if they received regular questionnaires.
NSCLC Outcomes: Clinical and Non-Clinical Evidence
August 8th 2022

NSCLC Outcomes: Clinical and Non-Clinical Evidence

An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC.
Using Clinical Pathways to Treat NSCLC
August 8th 2022

Using Clinical Pathways to Treat NSCLC

Edward Arrowsmith, MD, describes the value of using clinical pathways in NSCLC therapy and how they are used at his institution, including their multiple sites of care.
Immunotherapy Plus Chemoradiation Improves NSCLC Outcomes
August 5th 2022

Immunotherapy Plus Chemoradiation Improves NSCLC Outcomes

Jared Kaltwasser
New real-world evidence on non–small cell lung cancer (NSCLC) aligns with the results of a 2017 clinical trial.
Image of a lung scan and a stethoscope
July 31st 2022

New Screening Recommendations Not Likely to Erase Lung Cancer Disparities

Jared Kaltwasser
More people are eligible for screening, but a new analysis suggests lung cancer disparities are due to more than eligibility status.
Color-coded image of DNA
July 25th 2022

KRAS Inhibition May Improve Efficacy of Immune Checkpoint Blockade in Lung Cancer

Jared Kaltwasser
The research may eventually help clinicians optimize therapy with immune checkpoint inhibitors.
Alexander Spira, MD
July 22nd 2022

In KRYSTAL-1, Adagrasib for NSCLC Has 43% Response Rate

Mary Caffrey
Image of a lung cancer consult
July 19th 2022

Trigger Systems Can Help Clinicians Better Serve Patients With Poor Cancer Prognosis

Jared Kaltwasser
Two studies showed how hospital-based trigger systems could help guide patients toward appropriate goals of care and in some cases palliative care.
The Future of NSCLC Management
July 18th 2022

The Future of NSCLC Management

Our experts conclude with their final thoughts on the future of NSCLC treatment.
Educating Payers and Providers on Advanced NSCLC With Mutations
July 18th 2022

Educating Payers and Providers on Advanced NSCLC With Mutations

Three medical professionals recommend educational needs for both payers and providers within the NSCLC treatment landscape.
KRAS Inhibitors in Frontline and Combination Therapy
July 18th 2022

KRAS Inhibitors in Frontline and Combination Therapy

Drs Sabari and Spira comment on the use KRAS inhibitors in both frontline and combination therapies.
Image of lungs
July 15th 2022

Immunotherapy Changing NSCLC Care, But Many Questions Remain

Jared Kaltwasser
A new review notes advances and remaining questions, and calls for better incorporation of data from veterans.
Final Thoughts on ILD
July 12th 2022

Final Thoughts on ILD

The panel concludes by offering key takeaways for viewers and listeners on ILD therapy.
Unmet Needs and New Developments in ILD Treatment
July 12th 2022

Unmet Needs and New Developments in ILD Treatment

The panel participants relay unmet needs they have found when treating ILD, and discuss promising therapy developments that could improve the treatment landscape.
Image of data analysis
July 11th 2022

NSCLC Outcomes Improve, but Racial, Ethnic Disparities Remain

Jared Kaltwasser
Better screenings and improved therapies have helped boost non–small cell lung cancer (NSCLC) outcomes, but investigators said some patient groups have seen less improvement than others.
Resistance to KRAS G12C Inhibition
July 11th 2022

Resistance to KRAS G12C Inhibition

Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition.
Treatment Options for KRAS-Mutated NSCLC
July 11th 2022

Treatment Options for KRAS-Mutated NSCLC

Alexander Spira, MD, PhD, FACP, and Joshua Sabari, MD, detail possible therapeutic options for KRAS-mutated NSCLC, focusing on adagrasib and treating brain metastases.
<12345678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo